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Abstract
Purpose: To systematically review the literature pertaining to the link between cocaine and either
arterial or venous thrombosis.
Procedures: Narrative systematic review of Medline, CINAHL, Embase, Psycinfo and Cochrane
databases supplemented by hand trawling of relevant journals and reference lists up to April 2007.
In-vivo studies and those with clinical endpoints were included in the review.
Results: A total of 2458 abstracts led to 186 full-text papers being retrieved. 15 met the criteria
for inclusion in the review. The weight of evidence would support cocaine as a pro-thrombotic
agent. There is evidence of it activating thrombotic pathways. The effect of cocaine upon clinical
endpoints has not been quantified though there is evidence of an association between cocaine and
myocardial infarction particularly amongst young adults. Cocaine may also be a causal agent in
cerebrovascular accident though studies lacked sufficient power to determine a statistically
significant effect. There is a gap in the evidence pertaining to the issue of cocaine and venous
thrombosis.
Conclusion: Clinicians should consider questioning for cocaine use particularly amongst young
adults who present with cardiac symptoms. More epidemiological work is required to quantify the
effect of cocaine upon both arterial and venous clotting mechanisms.
Background
Globally cocaine use is common. The most recent data
available for England showed a total of 147781 drug users
in contact with drug treatment services and general practi-
tioners for the current year 2007 [1]. The United Kingdom
has the highest prevalence of both lifetime and recent
cocaine use in Europe, and use tends to be highest in
urban areas. Recent national population surveys con-
ducted in Europe showed a lifetime prevalence of 6.8%
for the UK adult population (i.e. used cocaine at least
once). Levels of use among younger adults tend to be
higher than the population average. The range of lifetime
experience among European15- to 34-year-olds is
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between 1% and 11.6% and the UK is at the top of this
range [2].
Cocaine is derived from leaves of the erythroxylum coca
plant [3] which is grown in the Andes mountains in South
America. Cocaine is available in different forms. When
treated with hydrochloric acid it becomes cocaine hydro-
chloride salt which is water soluble and decomposes on
heating. Such properties make this form amenable to
intravenous injection, or snorting through the nasal
mucosa [4]. In contrast cocaine alkaloid (also known as
freebase or crack cocaine) is an insoluble crystalline sub-
stance that that when heated converts to a stable vapour
that can be inhaled [4]. Whilst freebase and crack are the
same chemical form of cocaine, they are made by different
techniques. Freebase is made by dissolving cocaine hydro-
chloride in water then adding ammonia as a base and
ether as a solvent. The cocaine base dissolves in the ether
layer which is then extracted by evaporating ether at low
temperatures. Cocaine freebase can then be mixed with
tobacco and smoked or heated in special cocaine pipes
and inhaled. Crack cocaine is made from dissolving
cocaine hydrochloride in water, and then heating with
baking soda. The cocaine base then precipitates into a
hard mass (often known as "rocks"). This form of cocaine
tends to be smoked [4], though can also be injected.
The properties of cocaine to cause vasoconstriction of the
arterial vasculature have been well documented [5]. How-
ever there have been a number of case reports and series
where cocaine has been implicated as the causal agent in
arterial thrombosis. There are case reports of thrombosis
in the renal artery [6], pulmonary artery [7], aorta [8], and
coronary arteries. In some of these case reports myocardial
infarction has occurred where there is no evidence of athe-
rocsclerosis [9]. This state is often referred to in the litera-
ture as "myocardial infarction with normal coronary
arteries". [10] The postulated mechanism of action is
adrenergically mediated increases in myocardial oxygen
consumption, vasoconstriction of large epicardial arteries
or small coronary resistance vessels leading to coronary
thrombosis [10]. However it has also been postulated that
such infarctions could be due to a state of blood hyperco-
agulability leading to arterial thrombosis [10]. Hyperco-
agulability occurs with low plasma tissue plasminogen
activator activity, high tissue plasminogen activator inhib-
itor activity, factor XII deficiency or abnormal platelet
aggregation [10]. This raises the hypothesis as to whether
in addition to properties of vasospasm cocaine is a pro-
thrombotic agent.
Cocaine has also been implicated in cases of cerebral
thrombosis [11] but also in cases of haemorrhagic cere-
brovascular accidents [11]. It has been postulated that
haemorrhagic cerebral infarcts in cocaine use are due to
episodic hypertension due to the vasoconstricting proper-
ties of cocaine [12].
As well as being implicated as the causal agent in the proc-
ess of arterial thrombosis, cocaine has also been impli-
cated as the causal agent in venous thrombosis as it has
been associated with case reports of upper extremity deep
vein thrombosis [13].
The evidence from in-vitro studies is conflicting with
some results showing an increase in platelet activation fol-
lowing cocaine administration [14] and other results
showing cocaine to be an inhibitory factor in platelet
coagulation (and hence thrombus formation) [15,16].
However biochemical mediators can act differently in-
vitro to the human in-vivo setting. Similarly the results of
animal studies have shown conflicting reports on the abil-
ity of cocaine to induce platelet formation [17,18]. There-
fore this research sought to undertake a systematic review
of human in-vivo studies, and studies with a clinical end-
point studying the effect of cocaine on either the arterial
or venous clotting mechanisms.
Methods
The following medical databases were searched: Medline
(1966 to April 2007), EMBASE (1980 to April 2007), psy-
cINFO (1985 to April 2007), CINAHL (1982 to April
2007), Web of Science (1981 to April 2007) and
Cochrane Database to April 2007. A full copy of the search
strategy is available from the authors upon request. Briefly
the umbrella terms of "cocaine dependence", "thrombo-
genensis" and "clotting factors" were used to identify pri-
mary research relating to the topic area.
Additionally the contents pages of high impact journals
were hand trawled for the period January 1999 to May
2007. The review was not limited to publications in the
English language and the potential for identifying relevant
grey literature material was through discussion with
experts in the field. The search was undertaken by three
researchers (NW, RE and MM) who independently
assessed which full-text papers should be retrieved from
the abstracts and reference lists. Discrepancies were
resolved by discussion. Upon retrieval of the full-text
papers, the names of the authors were concealed so that
reviewers were blind to the author team of the papers
under scrutiny.
The following inclusion criteria were applied: observa-
tional or intervention studies of participants with diag-
nosed cocaine abuse or dependence, or intervention
studies conducted amongst human subjects administered
pharmacological cocaine and evaluating any one of the
following outcomes: clinical outcomes of thrombogenesis
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vein thrombosis), surrogate markers of raised clotting fac-
tors. As the vasoconstricting properties of cocaine are well
known, studies which considered only the endpoint of
vasospasm were excluded.
Additionally the following papers were excluded: editori-
als, discussions, opinion pieces, qualitative studies, quan-
titative in-vitro studies, animal studies, descriptive
studies, observational studies that did not have a control
group.
Selection of papers for inclusion in the review entailed
independent assessment by three researchers (JM, TG and
NW). Any discrepancy was resolved by a fourth independ-
ent researcher checking the papers (SG). If agreement
could still not be reached then disagreement would be
resolved by discussion.
The protocol for the systematic review entailed devising a
checklist to assess the quality of the papers. The section of
the protocol pertaining to intervention studies was
informed by the recommendations of the Cochrane hand-
book for conducting systematic reviews[19]. Quality crite-
ria for assessing observational cohort studies utilised
established principles of research rigour in epidemiologi-
cal research [20]. At the outset it was written into the pro-
tocol that negative findings of statistical significance
should not be excluded. Similarly it was determined that
underpowered studies whereby a statistically significant
effect of an intervention could not be demonstrated were
not excluded purely on the basis of lack of statistical
power.
A checklist was developed to assess the quality of the stud-
ies which is available from the authors on request.
With respect to data analysis, a meta-analysis was not per-
formed as the review protocol did not limit inclusion
solely to RCTs. Rather in line with current recommended
practice for analysis of non-randomised studies, a narra-
tive analysis of the papers was adopted to elicit common
themes emerging from the studies [21].
Results
The review found results of studies with clinical endpoints
and also studies evaluating the effect of cocaine upon the
surrogate markers of clotting factors. A total of 2628
abstracts led to 218 full-text papers were retrieved and 18
were included in the review (see figure 1). Summaries of
the papers and their findings are shown [see Additional
file 1].
Clinical outcomes
Papers were retrieved which described the effect of cocaine
upon coronary artery vasculature and cerebral arteries.
Results pertaining to these clinical endpoints are
described below.
Coronary artery vasculature
Evidence for the possible thrombotic effects of cocaine
comes from the study conducted by Mittleman et al in 64
medical centres in the USA [22]. Using case control cross-
over methodology it showed that within 1 hour of using
cocaine there was a 23.7 times increased relative risk of
MI. The elevated risk rapidly decreased after one hour.
This concurs with the finding by Qureshi et al that persons
reporting regular cocaine use had a significantly higher
likelihood of non-fatal MI than non-users (age adjusted
odds ratio 6.4) [23]. It would appear that the participants
with MI presented in the Quereshi et al paper were further
analysed using case control methodology and presented
in a further paper [24]. Results showed that compared to
controls with MI, cocaine users with MI were younger
with a lower number of coronary artery disease risk fac-
tors. Angigography revealed a higher level of multivessel
disease (65% vs 32%, P < 0.05, confidence intervals not
stated) and a higher number of coronary artery lesions (≥
50% 2.3 per patients vs 1.6/patient, P < 0.05, confidence
intervals not stated).
A case control study conducted by Tanenbaum et al dem-
onstrated a statistically significant association between
illicit cocaine use and major electrocardiograph (ECG)
changes compared to schizophrenic controls [25]. Such
ECG changes included myocardial infarction, myocardial
ischaemia or bundle branch block. However an important
limitation of this study was that cigarette smoking was
more common in the cocaine using group compared to
the control group and multivariate analysis to control for
smoking effect was not conducted.
The findings by Dressler et al showed that autopsy coro-
nary artery pathology was greater in those who had toxic
levels of cocaine in the blood compared to those who did
not [26]. They postulate that either coronary atherosclero-
sis is accelerated by cocaine addiction, or that cocaine pro-
vides a fatal stress in patients with premature coronary
atherosclerosis from other causes. Evidence for the former
comes from the finding by Amin et al showing that of
those cocaine users presenting to medical departments
with chest pain, there was no statistically significant differ-
ence in coronary risk factors between those who devel-
oped acute myocardial infarction and those who did not
[27]. This would suggest that cocaine accelerates athero-
sclerosis rather than acting as a stress to those with prema-
ture atherosclerosis.
Such a process of cocaine accelerating a process of athero-
sclerosis is consistent with the findings from autopsy stud-
ies.Substance Abuse Treatment, Prevention, and Policy 2007, 2:27 http://www.substanceabusepolicy.com/content/2/1/27
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An autopsy study by Kolodgie et al 1991 reported on dif-
ferences in number of mast cells in coronary artery sec-
tions plotted against degree of cross-sectional luminal
narrowing [28]. It showed a positive correlation in
patients with cocaine-associated sudden death and
thrombosis compared to sudden death and thrombosis in
those without a history of cocaine abuse. The authors con-
cluded that mast cells with rich stores of histamine play an
important part in the pathogenesis of coronary vasospasm
and thrombosis, possibly by increasing lipid uptake and
therefore promoting atherogenesis. A further study
Kolodgie et al 1992 showed statistically significantly
greater percentage of sudanophilia in thoracic aorta and
abdominal aortae in those cases with a positive toxicolog-
ical screen for cocaine compared to those with a toxicolog-
ical screen that was negative for cocaine [29].
Sudanophilia is a marker for fatty streaks, which is an
indicator of early atherosclerosis.
An autopsy study by Virmani did not reach firm conclu-
sions [30]. Two of the cocaine cases had severe coronary
atherosclerosis and one an occlusive coronary thrombus.
However numbers from the control group with athero-
sclerosis or coronary thrombus was not stated. Whilst
cocaine users showed a statistically significant increase in
the histological changes of myocarditis (as shown by
mononuclear infiltrate), contraction band necrosis was
also less in the cocaine using group.
Whilst the findings of the autopsy studies appear to con-
cur with those studies evaluating a clinical outcome, they
do have limitations. The key limitation of the autopsy
studies by Kolodgie [28,29] and by Virmani [30] is that
the opportunity to calculate the relative risk of atheroscle-
rosis in cocaine users compared to non-cocaine users was
missed.
Cerebral pathology
The paper by Fessler et al reported the findings of sub-
arachnoid haemorrhage in those who used cocaine com-
pared to a control group of non-cocaine using patients
[31] found that compared to the non-cocaine using
group, the cocaine using group had a younger age at pres-
entation and a smaller aneurysm diameter suggesting that
cocaine accelerates pre-existing pathology.
However, the Quereshi study despite recruiting 10085
participants concluded that there was no statistically sig-
nificant increased risk of non-fatal stroke amongst fre-
quent cocaine users [23]. However it would appear from
the multi-variate adjusted odds ratio that despite large
numbers recruited into the study it was underpowered to
detect a difference (multivariate adjusted odds ratio 0.49,
95% CI 0.01–7.69). A slightly larger case control study of
10368 women however found an elevated risk of stroke in
users of cocaine (Adjusted odds ratio for any cocaine 13.9,
95%CI: 2.8–69.4) [32]. The study sought to quantify the
associations between stimulants and either ischaemic or
haemorrhagic stroke. However the researchers aggregated
data for cocaine and amphetamine use making interpreta-
tion difficult. Research aggregating data for both cocaine
and amphetamine was also published by Kaku & Lowen-
stein(1990) [33] which showed a temporal relationship
between stimulant use (either cocaine or amphetamine).
The closer the time to last cocaine use, the greater the
strength of association with stroke.
Therefore the current body of evidence would appear to
support an association between stimulants and cerebrov-
ascular accident with the most significant stimulant risk
factor being cocaine. However more research is need to
quantify the effect of cocaine upon the risk of thrombotic
rather than haemorrhagic cerebrovascular accident.
Clotting factors
The study by Heesch et al 2000 entailed administering
pharmacological cocaine at a dose of 2 mg/kg to healthy
volunteers. Relative to placebo administration there was a
statistically significant increase in platelet factor 4, β-
thromboglobulin clotting factors. There was also an
Flow chart showing process of retrieval of papers included in  the systematic review Figure 1
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increase in platelet containing microaggregate formation
and a reduction in bleeding time [34]. This finding
appears to be more significant than the findings by the
same author reported in 1996 [35]. In this study whilst
cocaine was administered in-vivo, platelet aggregation
was induced in-vitro using either collagen, adenosine
phosphate epinephrine, or arachadonic acid. There was a
trend towards decreased aggregation regardless of which
drug was used. However following adenosine phosphate
administration there was a statistically significant greater
reduction in platelet aggregation in the cocaine group
compared to the placebo group.
A consistent theme emerges from the results of other in-
vivo studies of cocaine leading to an increase in clotting
factors. A study by Rinder et al aggregated cross-sectional
data from an observational study and baseline data from
a pilot controlled clinical trial [36]. The results were a
higher resting level of P-selectin positive platelets in
cocaine users compared to healthy controls which the
authors concluded could mediate a process of thrombo-
sis.
The study by Moliterno et al demonstrated a statistically
significant increase in plasminogen activator inhibitor
(PAI-1) after cocaine administration[37]. Elevated levels
of PAI-1 are associated with thrombogenesis. The bio-
chemical pathway for thrombolysis is such that tissue
plasminogen activator coverts plaminogen to plasmin
which in turn causes fibrinolysis by degrading fibrinogen
and fibrin clots. PAI-1 inactivates tissue plaminogen acti-
vator. The paper by Siegel et al 1999[38] showed an
increase in von Willebrand factor, haemoglobin, haemot-
ocrit and red cell count that was dose related to intrave-
nous cocaine administration. Changes were observed at a
dose of 0.4 mg/kg cocaine but not at a dose of 0.2 mg/kg.
The authors concluded that cocaine induced a transient
erythrocytosis that may increase blood viscosity. They also
concluded that an increase in von Willebrand factor with-
out a compensatory change in endogenous fibrinolysis
may trigger platelet adhesion, aggregation, and intravas-
cular thrombosis. A further study by Siegel et al reported
in 2002 used case-control methodology to compare clot-
ting factors in cocaine dependent users versus those who
abused but were not dependent on cocaine [39]. Those
with dependant cocaine usage showed elevations in C-
reactive protein, von Willebrand factor and fibrinogen.
Fibrinolytic activity and total cholesterol showed no dif-
ference between the 2 groups. The authors concluded that
the findings were consistent with a cocaine-related
inflammatory response with pro-thrombotic effects.
Discussion
The weight of evidence from both clinical and in-vivo
studies included in this review would suggest that cocaine
has pro-thrombotic properties and can be responsible for
early-age onset of cardiovascular morbidity and mortality.
It could be argued that observational studies with clinical
endpoints and in-vivo studies are too heterogenous to
allow firm conclusions to be drawn as the former consid-
ered the effect of exposure to illicit "street" cocaine,
whereas the latter considered the effect of pharmacologi-
cal cocaine. However we felt that having a search strategy
that limited the review to just to one of either clinical or
in-vivo studies would have been over-focussed and risk
missing important data. There is strong evidence for
cocaine being a risk factor for myocardial infarction and
moderately strong evidence for cocaine being a risk factor
for cerebrovascular accident.
Further the conclusions drawn from our review concur
with findings from the wider literature suggesting that
cocaine has a cardiotoxic effect that is not just limited to
thrombogenensis. The findings included in this review by
Mittleman et al of an elevated risk of MI one hour after
cocaine use concurs with a US based prospective observa-
tional study of 246 participants [22]. This study examined
the characteristics of cocaine associated chest pain and
found that pain occurred a median of 60 minutes after
cocaine use and persisted for up to 120 minutes [40]. A
case control study of 50 patients, whilst not considering
directly the outcome of thrombogenesis did demonstrate
an association between cocaine use and the presence of
contraction bands in the myocardium (which may act as
the anatomic substrate for arrhythmias associated with
cocaine use)[41]. A controlled clinical trial evaluating the
effect of cocaine on ECG and echocardiographic changes
before and after a single intravenous dose of high dose
cocaine showed a doubling in the frequency of hyperdy-
namic left ventricular wall segments after high dose
cocaine compared to placebo and dose related non-spe-
cific changes on ECG [42]. These findings concur with
ECG and echocardiographic study findings conducted on
52 chronic cocaine abusers.
Compared to controls, chronic cocaine abusers had
increased left ventricular posterior wall thickness,
increased septal wall thickness and higher left ventricular
mass index [43]. A controlled trial of 18 patients undergo-
ing cardiac catheterisation for evaluation of chest pain
found that post administration of cocaine, the magnitude
of vasoconstriction was greater in diseased areas (of athe-
rocsclerosis) compared to non-diseased areas[44]. Our
findings would suggest that recent cocaine use should be
routinely inquired of all young patients attending health
services with symptoms of chest pain. A USA based study
of 359 patients presenting to emergency departments with
chest pain of possible cardiac origin revealed 17% had
cocaine or cocaine metabolites in the urine [45]. They
tended to be younger than those without cocaine metab-Substance Abuse Treatment, Prevention, and Policy 2007, 2:27 http://www.substanceabusepolicy.com/content/2/1/27
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olites in the urine. A USA based retrospective cohort study
of cocaine associated myocardial infarction revealed a low
post MI mortality and the majority of complications
occurring within 12 hours of presentation [46]. It is possi-
ble that the relative young age of those with cocaine asso-
ciated MI protects against further complications.
The clinical management of those with cocaine induced
cardiovascular pathology has been discussed in the litera-
ture. Commentators practicing in the area of emergency
medicine have argued that those with suspected acute
cocaine induced myocardial ischaemia or infarction
should be treated similarly to those with acute coronary
syndromes but with some exceptions [47]. These include
administering benzodiazepines in the early management
to reduce the central nervous stimulatory effects of
cocaine; avoiding B blocker medication as it may exacer-
bate cocaine induced coronary artery vasoconstriction;
and a preference for percutaneous coronary intervention
over fibrinolysis as cocaine associated chest pain in young
cocaine users is associated with low mortality. Also many
patients are hypertensive and aortic dissection must be
considered. Therefore on balance the risk/benefit ratio
would not favour administration of fibrinolytics.
As regards primary prevention of cocaine induced cardio-
vascular morbidity, we could only find one study which
evaluated the effectiveness of aspirin. The study showed
that aspirin is ineffective at protecting against platelet
aggregation and cerebral hypoperfusion in cocaine users.
Rather abstinence from cocaine was shown to be effective
in reducing platelet abnormalities and increasing cerebral
perfusion [48].
Our findings raise further implications for research. There
is a need to quantify the absolute risk of circulatory mor-
bidity and mortality due to illicit cocaine use by utilising
longitudinal observational methodology with a control
group of non-cocaine users. Additionally more research is
needed to further understand the effect of cocaine upon
cerebral artery vasculature. The evidence for cocaine as a
causal agent in cases of cerebrovascular accident is not
conclusive. However the findings of this review concur
with the wider evidence base. An early descriptive paper
which reviewed the records of 3712 drug abusers and
highlighted 13 patients with cerebrovascular accident, of
these 7 were ischaemic in nature and the mean age was
34.2 years [49]. Such descriptive data would lend support
to more rigorous epidemiological work quantifying the
relative risk at developing an ischaemic cerebrovascular
accident following cocaine use.
Our review did not highlight any papers studying the
effect of cocaine upon venous vasculature. There are
descriptive studies hypothesising cocaine as the causal
agent in deep vein thrombosis [13]. It has been hypothe-
sised that it could be either cocaine itself or an adulterant
used to dissolve cocaine prior to injection in the blood-
stream that is the putative agent for thrombus formation
[13]. This area merits further in-depth research with more
specific questioning regarding the form and strength of
cocaine that is used for injection.
The effect of different forms of cocaine upon the circula-
tory system also merits further activity. We retrieved one
paper in which the authors had aggregated data from case
reports in the literature with their own case series [50].
They concluded that ischaemic and haemorrhogic strokes
were equally likely after taking alkaloidal (crack) form of
cocaine, whereas the cocaine hydrochloride form is more
commonly associated with haemorrhagic stroke. However
any attempt to control for confounders was not men-
tioned. This coupled with the fact that positive reporting
bias could not be excluded from the case reports which
informed the aggregate data means that firm conclusions
could not be drawn from the data. Similarly the findings
by Petitti et al [32] whilst adjusting for confounders only
presented adjusted odds ratios for risk of haemorrhagic or
ischaemic stroke in users of "cocaine and/or ampheta-
mine" which limits firm conclusions regarding the effect
of type of cocaine upon thrombogenensis.
Conclusion
In summary the weight of evidence would support the
hypothesis that cocaine is thrombogenic though more rig-
orous observational research with clinical endpoints is
needed to quantify relative risk. From our findings we
would suggest that where young people present with
symptoms consistent with acute cardiovascular events,
direct questioning should include all relevant drugs. As
regards primary prevention advice and support to become
abstinent from cocaine is more likely to improve health
outcomes than the provision of prophylactic aspirin.
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